Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A phase II open-label multi-centre single-arm study evaluating the efficacy of Glivec plus Hydroxyurea HU in patients with progressive glioblastoma multiforme GBM not receiving enzyme inducing anticonvulsant drugs EIACDs

To assess the clinical efficacy of the combined treatment of imatinib plus HU based on the objective overall response OR rateThis objective overall response rate is calculated as the rate of best overall response of complete response plus partial response CRPR to treatment

FieldValue
Modified
2019-04-21
Release Date
2018-04-16
Identifier
035bf6e6-b931-4ffa-9204-53012fc959d8
License
Public Access Level
Public